Kornimate/medical-research-clean huggingface dataset:
rapid flu tests in travelers with fever

Conditions: Influenza

Summary: influenza is a frequent cause of fever in returning travelers. usually diagnosis rests on the clinical picture. rapid flu tests are becoming increasingly popular, although their sensitivity and specificity are suboptimal. the objective of this study is to evaluate if rapid flu tests influence the medical management of returning travelers with fever, a population at intermediate risk for influenza infections.

travelers are at risk of acquiring infectious diseases. previous studies have estimated that about 11% of travelers develop fever during or shortly after their trip abroad. influenza has been shown to be one of the most important cause of fever amongst travelers. a sero-epidemiological survey showed that 27 of 211 patients (12.8%) with fever during or after a trip abroad developed antibodies against the influenza virus. another study showed that 13% of travellers, who consulted after return with flu-like symptoms, had pcr or culture-proven influenza. the incidence of influenza in travellers varies according to the seasons, but cases can be seen year round. in tropical countries transmission is year-long and in the southern hemisphere the flu epidemics occur during the summer of the northern hemisphere. in most hospitals no confirmatory test for influenza is routinely done. for special cases a pcr or viral culture can be requested, but the results are only available after 48 hours for the pcr and after several days for the culture. it is suspected that the inability to confirm the diagnosis of flu contributes to the request of a greater number of useless investigations and inappropriate use of anti-infective treatments. rapid diagnostic tests are easy to use, relatively cheap and they yield a result within a clinically relevant time frame (30 minutes). for the detection of influenza there are a variety of rapid diagnostic tests on the market. the reported sensitivities and specificities are quite variable, but the new generations report median sensitivities of 70 - 75% and median specificities between 90 and 95%. the rapid tests are considered most useful in patient populations with a significant proportion of influenza cases. the who encourages to use rapid diagnostic tests for influenza in returning travelers with fever, considering that this patient population is at significant risk of acquiring influenza during their trip. the aim of this study is to evaluate if rapid flu tests influence the medical management of returning travelers with fever

Eligibility criteria:
inclusion criteria: * adults 18 years or older * returning from abroad within the last 14 days * documented fever of 38oc or above or anamnestic fever + cough or sore throat within the last 4 days before the consultation. exclusion criteria: * unwillingness to participate

Keywords: influenza rapid flu test returning travelers with fever
effect of whole body vibration with weighted vest on motor function in children with spastic diplegia

Conditions: Cerebral Palsy

Summary: whole body vibration has been widely used in rehabilitation of individuals with disabilities as well as children with cerebral palsy. previous studies have demonstrated the efficacy of whole body vibration on balance, gross motor function, spasticity and bone density in children with cerebral palsy. however, adding extra weight during whole body vibration for children with cerebral palsy as a means of enhancing the potential effects of whole body vibration is unknown. therefore, the aim of this study is to examine the effect of whole body vibration with weighted vest on trunk control, balance and gross motor function in children with spastic diplegia.


Eligibility criteria:
inclusion criteria: * their age will range from 8-12 years, from both sexes. * level ii and iii of gross motor functional classification system * grade 1 and 1+ spasticity according to the modified ashworth scale * ability to understand and follow simple verbal instruc exclusion criteria: * uncontrolled epilepsy. * mental retardation or autistic features. * medication changes that could affect muscle strength or tone * significant visual or auditory problems according to medical reports (audio-vestibular and ophthalmic examination), * structural or fixed soft tissue deformities of the lower and/or upper extremities. * neurological or orthopedic surgery in the past 12 months in the lower and/or upper extremities. * botox injection in the lower and/or upper extremities in the past 6 months.

Keywords: cerebral palsy balance muscle strength spastic diplegia humac balance system
a clinical study to evaluate the effects of darusentan on safety and efficacy in subjects with resistant systolic hypertension receiving combination therapy with three or more blood pressure lowering drugs

Conditions: Hypertension

Summary: this is a research study of a new experimental drug called darusentan. darusentan is not currently approved by the u.s. food and drug administration (fda) for use in the united states, which means that a doctor cannot prescribe this drug. the purpose of this study is to determine if darusentan is effective in reducing systolic blood pressure in subjects with resistant systolic hypertension, despite treatment with full doses of three or more blood pressure lowering drugs, including a diuretic.


Eligibility criteria:
inclusion criteria: * subjects who are competent to provide written consent * aged 35 to 85 years * subjects with diabetes and/or chronic kidney disease must have a mean systolic blood pressure ≥130 mmhg * all other subjects must have a mean systolic blood pressure ≥140 mmhg * receiving and adhering to full doses of appropriate guideline-recommended antihypertensive drugs from three different classes of antihypertensive agents, including a diuretic * female subjects of childbearing potential must have a negative serum pregnancy test at the screening visit and a negative urine pregnancy test at the time of randomization. exclusion criteria: * average sitting systolic blood pressure ≥180 mmhg or diastolic blood pressure ≥110 mmhg at screening * serum alt or ast \>2x uln * subjects who have experienced myocardial infarction, unstable angina, or a cerebrovascular accident (cva) within 6 month of the screening visit; or sick sinus syndrome or second or third degree atrioventricular block, chronic atrial fibrillation or recurrent atrial tachyarrhythmia, recurrent ventricular tachycardia, or symptomatic bradycardia * implanted cardioverter defibrillator (icd) that has fired for any arrhythmia within 3 months of screening or implanted pacemakers * symptomatic chf requiring treatment * hemodynamically significant valvular heart disease * hemodialysis or peritoneal dialysis; or history of renal transplant * diagnosis or recurrence of malignancy within the past 3 years * sleep apnea * subjects who perform alternating shift or night work * subjects who have participated in a clinical study involving another investigational drug or device within 1 month of the screening visit
compliance and endometriosis

Conditions: Endometriosis

Summary: endometriosis is defined as the presence of hormone-dependent endometrial tissue outside the uterine cavity. it is a chronic, painful and often disabling pathology during the normal activities of daily life. it affects 10% of women of childbearing age. it is therefore a real public health issue. the latest recommendations from the has and the cngof now recommend primary medical management of endometriosis in painful women who do not wish to become pregnant. it should be remembered that until very recently, the teams resigned themselves to carrying out surgical interventions in order to support the diagnosis (this is histological and requires a biopsy) and to treat the patient if possible. sometimes, this treatment was not possible from the outset, as the lesions appeared to be inaccessible, and additional hormonal treatment was therefore required. the current concept is to propose to patients a first hormonal suppressive treatment before a possible surgery. this therapeutic de-escalation should be considered in the light of the physiopathology of endometriosis, which is essentially based on the ovarian cycles, and indirectly on menstruation, which must then be suspended. however, a good number of patients are initially reluctant to undergo any kind of hormonal therapy, either because they have had a bad experience with hormonal contraception (intolerance) or because of a fear related to the possible complications of hormonal therapy with third or fourth generation pills, for example (thromboembolic risk). there is also a health alert at present concerning macro progestins in relation to the risk of meningioma. acceptance of the principle of instituting amenorrhea in order to relieve patients suffering from endometriosis requires prior information. in investigator's daily practice, they frequently deplore non-compliance, which is detrimental to the proper management of the disease. the effectiveness of hormonal treatment, which will institute a quiescence of hormonal activity, is not immediate. an analgesic and anti-inflammatory treatment is then added. investigators propose to compare the compliance of three drug strategies: analgesics alone, hormone therapy alone or hormone therapy and analgesics.


Eligibility criteria:
inclusion criteria: * be a woman with diagnosed painful endometriosis * have a prescription for medication (analgesics alone, hormone therapy alone or hormone therapy and analgesics). * speak and understand french * be a woman over 18 years old until menopause * agree to participate in the study exclusion criteria: - be a woman who has already had surgery for endometriosis

Keywords: endometriosis pain drug treatments hormonal treatment compliance amenorrhea recommendations menstruation quality of life efficiency
physiotherapists' placebo or nocebo communication regarding vr in cmp

Conditions: Communication; Chronic Pain

Summary: rationale: chronic musculoskeletal pain (cmp) is a common and disabling condition. physiotherapy is the most frequently administered non-pharmacological treatment option for patients with cmp and recently virtual reality (vr) was introduced in physiotherapy care as a novel treatment modality. proper communication about physiotherapy treatment (modalities) is important to improve treatment outcomes, by applying placebo effects enhancing communication and avoiding nocebo effects enhancing communication. however, yet is still unknown to what extent this applies to communication of physiotherapists about vr in patients with cmp. objective: to determine the effect of physiotherapists' placebo or nocebo therapeutic communication about vr, on treatment credibility and expectation in patients with cmp study design: web-based randomized controlled trial. study population: 100 participants intervention: the placebo intervention group will be shown an educational video about vr, containing placebo effects enhancing verbal language. the nocebo intervention group will be shown an educational video about vr, containing nocebo effects enhancing verbal language. primary study parameters: the primary study parameters are treatment credibility and treatment expectation. treatment credibility and treatment expectations will be measured using the dutch credibility and expectancy questionnaire (ceq).


Eligibility criteria:
inclusion criteria: * aged ≥ 18 * access to the internet * provide informed consent * suffers from cmp exclusion criteria: * lacked comprehension of the dutch language * had experience with therapeutic vr
research study investigating how well semaglutide works in people with type 2 diabetes suffering from overweight or obesity

Conditions: Obesity; Overweight

Summary: this study will look at the change in the participant's body weight from the start to the end of the study. this is to compare the effect on body weight in people taking semaglutide (a new medicine) and people taking "dummy" medicine. in addition to taking the study medicine, the participant will have talks with study staff about healthy food choices, how to be more physically active and what else the participant can do to lose weight. overweight and obesity is associated with an increased risk of type 2 diabetes. therefore, weight loss has shown to have a beneficial impact on the blood sugar levels. the participant will either get semaglutide or "dummy" medicine - which treatment the participant get is decided by chance. the participant will need to take 2 injections at the same time once a week. the study medicine is injected with a thin needle in a skin fold in the stomach, thigh or upper arm. the study will last for about 1.5 years


Eligibility criteria:
inclusion criteria: * male or female, age greater than or equal to 18 years at the time of signing informed consent * body mass index (bmi) greater than or equal to 27 kg/m\^2 ' * history of at least one self-reported unsuccessful dietary effort to lose body weight * diagnosed with type 2 diabetes (haemoglobin a1c 7-10% (53-86 mmol/mol) (both inclusive)) 180 days or longer prior to the day of screening exclusion criteria: * a self-reported change in body weight greater than 5 kg (11 lbs) within 90 days before screening irrespective of medical records * renal impairment measured as estimated glomerular filtration rate (egfr) value of less than 30 ml/min/1.73 m\^2 (less than 60 ml/min/1.73 m\^2 in subjects treated with sodium-glucose cotransporter 2 inhibitors) according to chronic kidney disease (ckd)-epidemiology collaboration (epi) creatinine equation as defined by kidney disease: improving global outcomes (kdigo) 2012 by the central laboratory at screening * uncontrolled and potentially unstable diabetic retinopathy or maculopathy. verified by a pharmacologically pupil-dilated fundus examination performed by an ophthalmologist or an equally qualified health care provider (e.g. optometrist) within the past 90 days prior to screening or in the period between screening and randomisation
different durations of adjuvant anastrozole therapy after 2 to 3 years tamoxifen therapy in breast cancer

Conditions: Breast Cancer

Summary: the purpose of this study is to determine whether 6 years adjuvant anastrozole will improve the disease free survival compared to 3 years adjuvant anastrozole in postmenopausal hormone sensitive breast cancer patients, subsequent to 2-3 years tamoxifen


Eligibility criteria:
inclusion criteria: * postmenopausal patients with hormone receptor positive breast cancer who have already received 2 to 3 years of adjuvant tamoxifen, and who never had signs of loco-regional recurrences or distant metastasis exclusion criteria: * previous hormonal therapy as adjuvant breast cancer treatment besides tamoxifen. * previous history of invasive breast cancer within the last 10 years, other then the breast cancer that is currently treated with tamoxifen

Keywords: hormone sensitive primary breast cancer adjuvant treatment aromatase inhibitor
impact of implementing an infant driven feeding program on oral feeding and growth outcomes of medically fragile infants in the neonatal icu (nicu)

Conditions: Oral Feeding Outcomes; Growth; Length of NICU Stay

Summary: the specific aim of this pre-post trial is to compare data regarding oral feeding, length of stay, and growth outcomes of 100 nicu infants to these same outcomes following the implementation of a developmentally supportive, infant driven feeding program with the nicu staff, specifically the supporting oral feeding in fragile infants (soffi) infant feeding program on a second sample of 100 nicu infants at children's memorial hospital. the specific research questions considered in this study are: 1. what is the impact of implementing the soffi on the oral feeding outcomes of medically fragile infants in the nicu at discharge and at 3 months post-term? 2. what is the impact of implementing the soffi on the growth outcomes of medically fragile infants in the nicu at discharge and at 3 months post-term? 3. what is the impact of implementing the soffi on the length of stay of medically fragile infants in the nicu? 4. what is the impact of implementing the soffi on the clarity and consistency of nicu staff evaluations and communications related to managing oral feedings with medically fragile infants?


Eligibility criteria:
inclusion criteria: * infants of all gestations and diagnostic groups in this tertiary level nicu will be included in the sample exclusion criteria: * infants with medical diagnoses known to impact sucking and swallowing * infants unable to manage their oral secretions * infants who remain hospitalized beyond 3 months adjusted age * infants who expire or are transferred to another inpatient unit or hospital/facility prior to discharge from the nicu

Keywords: supporting oral feeding in fragile infants (soffi) infant oral feeding infant growth preterm infant oral feeding preterm infant growth neonatal intensive care unit (nicu)
the effect of human leukocyte antigen macthing on guiding tacrolimus regimen after liver transplantation

Conditions: Liver Transplantation; Graft Versus Host Disease; Graft Rejection; Drug-Related Side Effects and Adverse Reactions

Summary: the aim of this research is to design a randomized controlled clinical study, which is based on hla matching rate to guide tacrolimus regimen. in this study, the possibility of tacrolimus regimen guided by hla matching rate will be explored, the occurrence rate of gvhd and rejection reaction will be observed, and the occurrence time and degree of adverse reactions caused by immune inhibitors will be identified. in the meantime, providing a possible prospect for prevention of gvhd and reduction or removal of immune inhibitors.

liver transplantation is the most effective treatment for end-stage liver disease, yet long term survival is limited by acute and chronic rejection reaction and adverse reactions caused by immune inhibitors. however, effective guideline of immune inhibitors regimen after liver transplantation is lacking. human major histocompatibility antigens (hla) is crucial in renal transplantation, while the role in liver transplantation is unclear. it is reported that hla matching was closely related to the occurrence of graft versus host disease (gvhd) after liver transplantation. and by reducing or removing the immune inhibitors can change the course of illness, improve prognosis, at the same time conduce to induce immune tolerance. therefore, the investigators have the reason to believe that hla matching rate has closely association with postoperative immune status of patients after liver transplantation, which may guide immune inhibitors regimen. the aim of this research is to design a randomized controlled clinical study, which is based on hla matching rate to guide tacrolimus regimen. in this study, the possibility of tacrolimus regimen guided by hla matching rate will be explored, the occurrence rate of gvhd and rejection reaction will be observed, and the occurrence time and degree of adverse reactions caused by immune inhibitors will be identified. in the meantime, providing a possible prospect for prevention of gvhd and reduction or removal of immune inhibitors.

Eligibility criteria:
inclusion criteria: * patients signed informed consent，patients with good compliance exclusion criteria: * autoimmune liver disease,abo incompatibility,combined organ transplantation,re-transplantation

Keywords: tacrolimus histocompatibility antigens
human amnion membrane allograft and early return of erectile function after radical prostatectomy

Conditions: Prostate Cancer; Erectile Dysfunction Following Radical Prostatectomy

Summary: the purpose of this research study is to evaluate if placing a dehydrated human amnion chorion membrane (dhacm) over the nerves after removal of the prostate during surgery (radical prostatectomy) will allow an earlier recovery of erectile function and urinary control after surgery.


Eligibility criteria:
inclusion criteria: 1. men aged 40 to 80 years with localized prostate cancer who are undergoing bilateral nerve-sparing rarp at the university of miami (um). exclusion criteria: 1. men requiring any use of pads for urinary leakage. 2. men requiring the use of any non-oral erectile aids for erectile dysfunction (ed) 3. men with baseline epic26 scores \< 60. 4. previous treatment for prostate cancer. 5. previous history of pelvic radiation. 6. patients with impaired decision-making capacity.

Keywords: prostatectomy allograft membrane
beta-blockers for prevention of growth of small esophageal varices in cirrhosis: an randomized controlled trial (rct)

Conditions: Cirrhosis

Summary: background and aims: the efficacy of portal pressure reduction by beta blockers for the management of small (≤5 mm) esophageal varices in patients of cirrhosis is not clear. the present randomized controlled trial aims to address these issues. the investigators also assessed the utility of serial hvpg measurements in these patients. patients and methods: consecutive patients with cirrhosis with small varices, with no history of variceal bleed, were randomized to receive propranolol or placebo. these patients were further randomized to undergo no hvpg, only baseline hvpg, or serial hvpg measurement. propranolol was titrated to reduce heart-rate to 55/min.


Eligibility criteria:
inclusion criteria: * a clinical, radiological or histologic diagnosis of cirrhosis was made * age was between 18 and 70 years * esophageal varices were small (i.e. ≤5 mm or of grade 1 or 2 according to conn et al). exclusion criteria: * presence of previous variceal bleeding * previous medical, surgical or endoscopic treatment for portal hypertension * child-pugh score \>13 * neoplastic disease of any site * splenic or portal vein thrombosis * concurrent illnesses expected to decrease life expectancy to less than one year * pregnancy * contraindication to beta-blockers (atrioventricular block, sinus bradycardia with heart rate \<50 beats per minute, arterial hypotension with systolic blood pressure \<90 mm hg, heart failure, asthma, peripheral arterial disease, or diabetes needing insulin treatment) * concurrent anti-viral treatment during the study period * inability to perform follow-up * failure to give consent to participate in the study.
neuromodulation effect of laser acupuncture on stress urinary incontinence

Conditions: Stress Urinary Incontinence

Summary: background:stress urinary incontinence (sui) is the most common type of urinary incontinence in women, as it involves involuntary leakage of urine , the current study was to determine the neuromodulation effect of laser therapy on neurogenic acupoints in female with stress urinary incontinence (sui).

thirty women with sui were randomly divided into two equal groups; the control group received pelvic floor muscle training , while the study group received the same pelvic floor muscle training in addition to laser acupuncture on neurogenic acupoints . the outcome measures were pelvic floor muscle strength (pfms) , sui severity assessed by severity index (si) , and incontinence questionnaire-short form (iciq-sf). the outcome measures were assessed pre- and post-rehabilitation program.

Eligibility criteria:
inclusion criteria: * age ranged from 30 to 45 years old * body mass index (bmi) was less than 30 kg/m2, * all women were non-smokers and they had a sedentary life style exclusion criteria: * the participants were excluded if they had other types of urinary incontinence (urge or mixed) * urinary tract infection * pelvic organ prolapse * diabetes mellitus * respiratory diseases, chronic cough and constipation

Keywords: neuromodulation laser acupuncture neurogenic acupoints female stress urinary incontinence